Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis  

作　　者：Ruping Cai Chen Chang Xingjie Zhong Qiang Su 

机构地区：[1]Department of Rehabilitation Medicine,The Second Nanning People’s Hospital,Nanning,530031,China [2]Department of Cardiology,Guilin Medical University Affiliated Hospital,Guilin,541000,China

出　　处：《Cardiovascular Innovations and Applications》2022年第4期41-55,共15页心血管创新与应用(英文)

摘　　要：Objectives:According to the findings of randomized controlled trials,blood lipid levels in patients with coronary heart disease(CHD)can be significantly decreased through a combination of pitavastatin and ezetimibe;however,the effects and clinical applications of this treatment remain controversial.This meta-analysis was aimed at objectively assessing the efficacy and safety of pitavastatin and ezetimibe in lowering blood lipid levels.Design:Relevant studies were retrieved from electronic databases,including PubMed,Cochrane Library,Embase,China National Knowledge Infrastructure,VIP,and WanFang Data,from database inception to June 8,2022.The lev-els of low-density lipoprotein cholesterol,total cholesterol,triglycerides,and high-density lipoprotein cholesterol in patients’serum after treatment were the primary endpoint.Results:Nine randomized controlled trials(2586 patients)met the inclusion criteria.The meta-analysis indi-cated that pitavastatin plus ezetimibe resulted in significantly lower levels of LDL-C[standardized mean difference(SMD)=-0.86,95%confidence interval(CI)(-1.15 to-0.58),P<0.01],TC[SMD=-0.84,95%CI(-1.10 to-0.59),P<0.01],and TG[SMD=-0.59,95%CI(-0.89 to-0.28),P<0.01]than pitavastatin alone.Conclusions:Pitavastatin plus ezetimibe significantly decreased serum LDL-C,TC,and TG levels in patients with CHD.

关 键 词：PITAVASTATIN EZETIMIBE Coronary heart disease Blood lipid 

分 类 号：R97[医药卫生—药品]